LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Legal & Regulatory and Reimbursement/Stryker Cement Mixing System Cleared by FDA
Legal & Regulatory and Reimbursement

Stryker Cement Mixing System Cleared by FDA

March 31, 2017 1 min read Premium comments

Advertisement

Stryker Cement Mixing System Cleared by FDA
Stryker AutoPlex Cement Mixing System / Courtesy of Stryker Corporation
Secondary

Stryker Corporation now has FDA clearance to use the company’s own cements, implants, and the AutoPlex mixing and delivery system with its AVAflex balloon system to treat vertebral compression fractures (VCF).

The system mixes, transfers, and primes bone cement for delivery in less than 60 seconds through a single incision.

Stryker bought the technology from Becton, Dickinson and Company (BD) for an undisclosed amount in a deal that was finalized last year. The deal included BD’s CareFusion VCF portfolio, which included the AVAmax, AVAflex, AVAtex, and AVAprep products.

The company says surgeons may use either a bipedicular or unipedicular approach and that recent studies show the former produces a more stable vertebrae but the latter is less invasive and allows for quicker surgery and recovery times.

According to Stryker, the AVAflex balloon system provides “bipedicular results with a unipedicular approach” and the system’s 30mm balloon is the longest currently available on the market. The 11-guage size allows surgeons to complete the procedure through one incision with a smaller needle. One insertion, rather than two, reduces risk of complications.

CareFusion Corporation, a subsidiary of BD, first received FDA clearance for AVAflex in 2015, and Michael Verdolin of Verdolin Pain Specialists commented in a statement that “the ability to steer a balloon through unipedicular approach cannot be overstated in its simplicity and efficiency.”

The FDA clearance document to Stryker states the system is intended for the “reduction of fractures and/or creation of a void in cancellous bone in the spine. This includes use during percutaneous vertebral augmentation. The system is to be used with cleared spinal Polymethylmethacrylate (PMMA) bone cements and Cortoss Bone Augmentation Material indicated for use during percutaneous vertebral augmentation procedures, such as kyphoplasty.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy